BMO Capital analyst, Gary Nachman, reiterated his Outperform rating and price target of $208.00 on shares of Jazz Pharmaceuticals (NASDAQ ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE